Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
Sonoma Pharmaceuticals Inc
Other Liabilities
Sonoma Pharmaceuticals Inc
Other Liabilities Peer Comparison
Competitive Other Liabilities Analysis
Latest Figures & CAGR of Competitors
Company | Other Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
|
Other Liabilities
$4.9m
|
CAGR 3-Years
89%
|
CAGR 5-Years
67%
|
CAGR 10-Years
12%
|
|
Johnson & Johnson
NYSE:JNJ
|
Other Liabilities
$25B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
5%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Other Liabilities
$6.7B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
6%
|
CAGR 10-Years
9%
|
|
Pfizer Inc
NYSE:PFE
|
Other Liabilities
$25.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
5%
|
|
Merck & Co Inc
NYSE:MRK
|
Other Liabilities
$8.3B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
0%
|
|
Eli Lilly and Co
NYSE:LLY
|
Other Liabilities
$7.9B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
6%
|
See Also
What is Sonoma Pharmaceuticals Inc's Other Liabilities?
Other Liabilities
4.9m
USD
Based on the financial report for Dec 31, 2023, Sonoma Pharmaceuticals Inc's Other Liabilities amounts to 4.9m USD.
What is Sonoma Pharmaceuticals Inc's Other Liabilities growth rate?
Other Liabilities CAGR 10Y
12%
Over the last year, the Other Liabilities growth was 10%. The average annual Other Liabilities growth rates for Sonoma Pharmaceuticals Inc have been 89% over the past three years , 67% over the past five years , and 12% over the past ten years .